Carbon Biosciences

Carbon Biosciences is a biotechnology company headquartered in Boston, Massachusetts, dedicated to advancing novel parvovirus-derived gene therapies. Founded by Longwood Fund and gene therapy pioneers Dr. John F. Engelhardt and Dr. Robert M. Kotin, and led by President and CEO Dr. Joel Schneider, the company is expanding the therapeutic potential of gene therapy through its proprietary platform. This platform leverages novel parvoviruses, tested under natural pressures, to target specific tissues and carry larger payloads with minimal neutralizing immunity and the potential for re-dosing.